The development of epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) has resulted in significant improvements in the treatment outcomes of patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.